Biopharma thought leadership
Advancing gene therapy scale-up challenges
As the biopharmaceutical industry sharpens its focus on gene therapy, opportunities for advancements and challenges in manufacturing processes still remain. Dr. Ger Brophy, executive vice president of biopharma production at Avantor, offers insights on how the biopharma industry can evolve its processes through lessons learned from manufacturing monoclonal antibodies (mAbs) or vaccines, improving supplier collaboration, and other factors.
Addressing Key Challenges Optimizing Downstream Bioprocessing
The term “optimize” is often applied to complex manufacturing, automation and business processes and implies that the most efficient function of all the elements of a process – technologies, sequences and procedures – has not been achieved...
Managing Single Use Supply Chain
With the rapid growth of single-use systems (SUS) for drug production, especially by drug manufacturers with multiple locations across the globe, there are many risks associated with underestimating the regulatory compliance, manufacturing and quality requirements of these systems...
Optimizing Upstream Bioprocessing
Despite significant advances made in recent years to increase biologic yields as well as the intensity and consistency of these processes, there is still the potential for innovation in this area in order to reach more efficient production of therapeutic proteins...
Considerations in Controlling Glycosylation
Continued expansion of the biosimilar marketplace has led to many commercial opportunities and technical challenges...
Challenges in Chromatography
Processing times can be reduced and yields increased by utilizing new hydrophobic interaction chromatography tools.
Opportunities and challenges in cell and gene therapy development
Q&A interview with Ger Brophy, Executive Vice President for Biopharma Production at Avantor.